- Home
- DMB vs ORGO Comparison
DMB vs ORGO Comparison
Compare DMB & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DMB | ORGO |
|---|---|---|
| Founded | 2013 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 203.6M | 181.4M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | DMB | ORGO |
|---|---|---|
| Price | $9.44 | $1.40 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 75.7K | ★ 534.3K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 4.17% | N/A |
| EPS Growth | N/A | ★ 1600.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $564,169,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $37.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 17.04 |
| 52 Week Low | $9.35 | $1.34 |
| 52 Week High | $11.28 | $7.08 |
Technical Indicators
Market Signals| Indicator | DMB | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 25.76 | 31.90 |
| Support Level | N/A | $1.34 |
| Resistance Level | $11.19 | $2.55 |
| Average True Range (ATR) | 0.16 | 0.06 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 17.44 | 17.65 |
Price Performance
Historical ComparisonAbout DMB BNY Mellon Municipal Bond Infrastructure Fund Inc.
BNY Mellon Municipal Bond Infrastructure Fund, Inc. is a diversified closed-end management investment company. The fund's investment objective is to provide as high a current income exempt from regular federal income tax as is consistent with the preservation of capital. It invests in transportation, energy and utilities, social infrastructure, and water and environmental sectors.
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.